A latest research paper was published in Oncotarget’s Volume 13 on December 17, 2022, entitled, “Serum microRNAs as latest criteria for referral to early palliative care services in treatment-naïve advanced cancer patients.”

A serious obstacle to the implementation of early palliative care (EPC) is the shortage of objective criteria for referral to EPC. Circulating microRNAs (miRNAs) have been recognized as promising biomarkers.

In the present study, researchers Tomofumi Miura, Shuichi Mitsunaga, Juntaro Matsuzaki, Satoko Takizawa, Ken Kato, Atsushi Ochiai, and Takahiro Ochiya from National Cancer Center Research Institute, National Cancer Center Hospital, Keio University, Toray Industries, Inc., and Tokyo Medical University investigated objective definitions for referral to EPC using microRNA. A complete of 178 serum samples were obtained from patients with lung, gastrointestinal, colorectal, bile duct, pancreas, and bladder cancers who were treatment-naïve and received chemotherapy between January 2011 and December 2013 at National Cancer Center Hospital East.

“The aim of the current study was to develop predictive models using serum miRNAs for patients who [were] admitted to a PCU [palliative care unit] ≤6 months after starting anti-tumor treatment.”

The team investigated expression levels of miRNAs using microarrays. The first final result was prediction of admission to a palliative care unit ≤6 months after first visit. Diagnostic models using clinical characteristics, miRNAs and mixtures of each were constructed. The miRNA models were constructed using 6 miRNA levels.

The perfect areas under the receiver operating characteristic curve (AUCs) of the clinical model was 0.741, while the common AUCs of miRNA-based models and combination models were 0.769 and 0.806, respectively. Combination models showed higher AUCs than the clinical model (p < 0.023). The researchers assert that the current combination models might offer latest objective definitions for referral to EPC and thus contribute to real-world implementation of EPC.

“The current study developed a predictive model using miRNA for patients admitted to a PCU ≤6 months after starting anti-tumor treatment. The current models might offer objective criteria for oncologists to facilitate the referral of patients to the EPC.”

Source:

Journal reference:

Miura, T., et al. (2022) Serum microRNAs as latest criteria for referral to early palliative care services in treatment-naïve advanced cancer patients. Oncotarget. doi.org/10.18632/oncotarget.28327.